BiotechTube
Profound Medical

Profound Medical

PROF
Canada

Profound Medical is pioneering a new category of incision-free, image-guided therapeutic ablation. The company's core technology platform integrates real-time magnetic resonance imaging (MRI) with therapeutic ultrasound to enable precise, predictable, and radiation-free tissue ablation. With its TULSA-PRO® system commercially available in the U.S., Europe, and other markets, Profound is targeting the large and growing market for prostate disease treatment, including prostate cancer and benign prostatic hyperplasia (BPH). The company is publicly traded and continues to advance clinical evidence and expand commercial adoption.

profoundmedical.com

PROF · Stock Price

USD 5.151.35 (-20.77%)
Market Cap: $195.6M

Historical price data

AI Company Overview

Profound Medical is pioneering a new category of incision-free, image-guided therapeutic ablation. The company's core technology platform integrates real-time magnetic resonance imaging (MRI) with therapeutic ultrasound to enable precise, predictable, and radiation-free tissue ablation. With its TULSA-PRO® system commercially available in the U.S., Europe, and other markets, Profound is targeting the large and growing market for prostate disease treatment, including prostate cancer and benign prostatic hyperplasia (BPH). The company is publicly traded and continues to advance clinical evidence and expand commercial adoption.

UrologyOncology

Technology Platform

Integrates real-time magnetic resonance imaging (MRI) with transurethral therapeutic ultrasound ablation and closed-loop temperature feedback for precise, incision-free tissue ablation.

Opportunities

Significant growth opportunity lies in capturing market share in the large prostate cancer and BPH treatment markets by displacing invasive surgeries and radiation.
Expansion of clinical indications (e.g., salvage therapy) and potential platform application to other disease areas represent longer-term opportunities.

Risk Factors

Key risks include slow commercial adoption by urologists, challenges in securing adequate and stable insurance reimbursement, intense competition from established and new technologies, and reliance on capital markets for funding prior to achieving profitability.

Competitive Landscape

Competes in prostate ablation with HIFU (e.g., EDAP TMS), cryoablation, and established surgery/radiation. In BPH, competes with other minimally invasive therapies like Rezūm and UroLift. Profound's key differentiation is its real-time MRI guidance and closed-loop feedback for precision.